Peptide vaccine plus immunotherapy for biliary tract cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized peptide vaccine combined with two immunotherapy drugs (durvalumab and tremelimumab) for patients with biliary tract cancer whose tumors have specific genetic changes. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with biliary tract cancer (cancer of the bile ducts or gallbladder).
- You have already received treatment with gemcitabine, cisplatin, and an immunotherapy drug (like pembrolizumab or nivolumab).
- Your cancer has a specific genetic change (called an oncogenic mutation) that the study vaccine is designed to target.
- You are willing to have a tumor biopsy at the start of the study and again during treatment.
- You have an ECOG performance status of 0 or 1 (meaning you are fully active or able to carry out light work).
- You have adequate organ and bone marrow function based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (pembrolizumab) given before and after surgery for people with bile duct or gallbladder cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a new combination of treatments—a wearable device that sends electric fields to the tumor area (tumor-treating fields) plus immunotherapy (durvalumab) and chemotherapy (gemcitabine/cisplatin)—for people with advanced bile duct or gallbladder cancer. It may be an option if you haven't had chemotherapy for advanced disease before.
Hear when a new Biliary Tract Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.